Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ta Yang

Showing results (131-140 of 310) with videos related to

Pageof 31
Sort By:
Chang Gung Medical Journal|February 27, 2009
A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancerJohn Wen-Cheng Chang, Thomas Chang-Yao Tsao, Cheng-Ta Yang, et al.
Cancers|February 15, 2022
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung AdenocarcinomaChiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 24, 2024
Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapyPing-Chih Hsu, John Wen-Cheng Chang, Li-Chung Chiu, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2006
p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatmentMiao-Fen Chen, Wen-Cheng Chen, Chun-Te Wu, et al.
Oncology Letters|January 20, 2017
Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancerMing-Szu Hung, I-Chuan Chen, Paul-Yann Lin, et al.
Journal of Cellular and Molecular Medicine|June 10, 2017
Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathwayLi-Fu Li, Kuo-Chin Kao, Yung-Yang Liu, et al.
Journal of Cancer Research and Clinical Oncology|March 23, 2010
Second primary esophageal or lung cancer in patients with head and neck carcinoma in Taiwan: incidence and risk in relation to primary index tumor siteMin-Chi Chen, Ping-Tsung Chen, Chunghuang Hubert Chan, et al.
Epigenomics|September 10, 2025
MicroRNAs signatures in small extracellular vesicles for psychological resilience in young adults using machine learningChia-Hsuan Li, Bao-Yu Chen, Chih-Wei Lin, et al.
Cancers|August 27, 2021
Predictors of Invasive Adenocarcinomas among Pure Ground-Glass Nodules Less Than 2 cm in DiameterWen-Chi Hsu, Pei-Ching Huang, Kuang-Tse Pan, et al.
The Kaohsiung Journal of Medical Sciences|December 31, 2009
Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern TaiwanCheng-Ta Yang, Jen-Yu Hung, Chun-Liang Lai, et al.
Pageof 31

Showing results (131-140 of 310) with videos related to

Sort By:
Pageof 31
Chang Gung Medical Journal|February 27, 2009
A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancerJohn Wen-Cheng Chang, Thomas Chang-Yao Tsao, Cheng-Ta Yang, et al.
Cancers|February 15, 2022
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung AdenocarcinomaChiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 24, 2024
Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapyPing-Chih Hsu, John Wen-Cheng Chang, Li-Chung Chiu, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2006
p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatmentMiao-Fen Chen, Wen-Cheng Chen, Chun-Te Wu, et al.
Oncology Letters|January 20, 2017
Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancerMing-Szu Hung, I-Chuan Chen, Paul-Yann Lin, et al.
Journal of Cellular and Molecular Medicine|June 10, 2017
Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathwayLi-Fu Li, Kuo-Chin Kao, Yung-Yang Liu, et al.
Journal of Cancer Research and Clinical Oncology|March 23, 2010
Second primary esophageal or lung cancer in patients with head and neck carcinoma in Taiwan: incidence and risk in relation to primary index tumor siteMin-Chi Chen, Ping-Tsung Chen, Chunghuang Hubert Chan, et al.
Epigenomics|September 10, 2025
MicroRNAs signatures in small extracellular vesicles for psychological resilience in young adults using machine learningChia-Hsuan Li, Bao-Yu Chen, Chih-Wei Lin, et al.
Cancers|August 27, 2021
Predictors of Invasive Adenocarcinomas among Pure Ground-Glass Nodules Less Than 2 cm in DiameterWen-Chi Hsu, Pei-Ching Huang, Kuang-Tse Pan, et al.
The Kaohsiung Journal of Medical Sciences|December 31, 2009
Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern TaiwanCheng-Ta Yang, Jen-Yu Hung, Chun-Liang Lai, et al.
Pageof 31